Hormonal
Tirzepatide improves cardiovascular risk factors, including blood pressure, lipid profiles, and liver fat content, in patients with type 2 diabetes, without increasing the risk of major adverse cardiovascular events in high-risk patients.
Tirzepatide not only lowers blood sugar and helps with weight loss but also improves other heart health markers like blood pressure, cholesterol, and liver fat. For patients with type 2 diabetes who are at high risk for heart problems, tirzepatide has not been shown to increase the risk of major cardiovascular events. This makes it a valuable option for comprehensive diabetes management, addressing both metabolic and cardiovascular health.
With regard to the cardiovascular profile of tirzepatide, clinical trials have shown an improvement in CV risk factors including systolic and diastolic blood pressure (BP), triglycerides, high-, very low, and low-density lipoproteins and waist circumference in participants receiving tirzepatide. Improvements in liver fat content and reduced visceral and subcutaneous abdominal adipose tissue volume have been shown with tirzepatide. In the SURPASS 4 trial, which included participants at high CV risk, the hazard ratio for major adverse CV events for tirzepatide treatment compared with glargine was 0.74 (95% CI 0.51–1.08), indicating CV risk was not increased.
Why this rating
Based on phase 3 trial data, but long-term CV event data is still under investigation (SURPASS-CVOT).
Source
Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects
Luis Alberto Vázquez et al. · Diabetes Therapy · 2024
DOI 10.1007/s13300-024-01587-6
More from this paper
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces clinically significant weight loss (mean 6.2–12.9 kg) and glycemic control (HbA1c reduction -1.87 to -2.59%) in adults with type 2 diabetes, with efficacy increasing with dose up to 15 mg weekly.Strong
- Tirzepatide enables a significant proportion of patients with type 2 diabetes to achieve normoglycemia (HbA1c < 5.7%) without clinically significant hypoglycemia, particularly when not combined with insulin or sulfonylureas.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →